Evrofarma SA (EVROF) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Evrofarma SA €0.68, price €3.99, upside -83.0%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value €0.6800 · Strongly overvalued (−83%)
!Quality 59/100
!Mixed Growth(revenue 5y +8.2 %/yr)
!Thin margins · 7.1% net margin (TTM)
!Moderate debt
!Mixed vs. peers(6/12)
!Moderate moat47/100
!Evidence only low, so the estimate is less certain
Watch Evrofarma SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €0.6355 – €4.31 · fair‑value band €0.5100 – €1.70 · the €3.99 price screens above the €0.6800 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Evrofarma in your weekly email
Every Wednesday you see whether Evrofarma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products. Evrofarma SA was founded in 1991 and is headquartered in Didymoteicho, Greece.
Stock analysis
Evrofarma SA (EVROF) currently trades at €3.99, while our model-based Fair Value estimate is €0.6800, implying the stock looks roughly 486.9% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €2.02 per share, and 0 of the 20 models we run sit above the €3.99 price.
Bear case: the Economic Profit group reads lowest at €0.3200, and 20 of the 20 models stay below the price. Evidence for this calculation is low.
Scenario range: €0.5100 (bear) to €1.70 (bull), the price of €3.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Evrofarma SA reported revenue of €45.4M in FY2022 versus €32.5M in FY2018, a compound +8.7%/yr. Reported net income was €1.4M in FY2022, compounding +9.7%/yr from FY2018.
Key figures
Market cap €54.6M · P/E ratio 50.5 · P/S ratio 1.58 · EPS (TTM) €0.0790 · Net margin 3.1% · Return on equity 18.3% · Return on assets (EBIT) 3.5% · Operating margin 8.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 62% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −2% fair-value upside, at −83%, EVROF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (€0.1900 to €2.81). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear €0.5100Fair Value €0.6800Bull €1.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+23.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.5% (2017) → 5.3% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 668 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−83% · Bottom 25%
Profitability
Return on equity (TTM)18% · Top 25%
Return on assets5% · Above median
Net margin (TTM)7% · Above median
Operating margin (TTM)8% · Above median
Growth and dividend
Revenue growth4% · Above median
Balance sheet
Debt / equity1.15× · Highest 25%
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (TTM)50.5× · Priciest 25%
P/B4.40× · Priciest 25%
P/S (TTM)1.25× · Pricier than median
EV/EBITDA11.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 30
FUTURE (revenue growth)22· sector 20
PAST (return on equity)73· sector 29
HEALTH (low debt)43· sector 96
DIVIDEND (yield)0· sector 58
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Evrofarma SA Fair Value". https://www.fairvalue-calculator.com/stock/EVROF
Frequently asked questions
Is Evrofarma SA (EVROF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.6800 versus a price of €3.99, about −83% upside (overvalued).
What is the fair value of EVROF?
Our model-based fair value for Evrofarma SA is €0.6800 (as of Sep 23, 2026), built from audited fundamentals. The current price: €3.99.
What is the quality score of EVROF?
Evrofarma SA has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evrofarma SA (EVROF)?
Our model-based price target is the fair value of €0.6800 (as of Sep 23, 2026) from 21 valuation models. Cautious scenario €0.5100, optimistic scenario €1.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Evrofarma SA stock forecast for 2026?
Our models put fair value at €0.6800, about −83% upside versus a price of €3.99 (overvalued). Cautious scenario €0.5100, optimistic scenario €1.70. The calculation is refreshed regularly with new filings.
What is the revenue of Evrofarma SA (EVROF)?
Evrofarma SA reported trailing-twelve-month revenue of about €49.4M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Evrofarma SA (EVROF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evrofarma SA it is €0.6800 per share (as of Sep 23, 2026), against a price of €3.99. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Evrofarma SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, EVROF trades above its calculated fair value: price €3.99, fair value €0.6800, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVROF?
No. The price is what the market pays today (€3.99); the fair value is what the company's own numbers justify (€0.6800). For Evrofarma SA the two are €3.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evrofarma SA worth?
The market values Evrofarma SA at about €54.6M (market capitalisation, as of Sep 23, 2026). Per share that is €3.99; our models calculate a fair value of €0.6800 per share.
What do the bullish and bearish scenarios say about EVROF?
Our models span a range for Evrofarma SA: cautious scenario €0.5100, base €0.6800, optimistic €1.70 per share (as of Sep 23, 2026, price €3.99). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EVROF?
Evrofarma SA trades at a price-to-earnings ratio of 50.5 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €0.6800 is built from several models across several years. Other multiples: P/B 4.4, P/S 1.2, EV/EBITDA 11.4.
How solid is the balance sheet of Evrofarma SA (EVROF)?
Balance-sheet figures for Evrofarma SA (as of Sep 23, 2026): return on equity 18.3%, debt of 1.15 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is EVROF from its 52-week high?
Evrofarma SA trades at €3.99, about 7% below its 52-week high of €4.31 and 62% above the low of €2.46 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.6800 is for.
Which stocks are comparable to Evrofarma SA?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evrofarma SA stock attractive at the current price?
The data as of Sep 23, 2026: price €3.99, calculated fair value €0.6800 (−83%), Quality Score 59/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVROF calculated?
We run Evrofarma SA through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.6800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Evrofarma SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evrofarma SA (EVROF)?
The closing price on Sep 24, 2026 was €3.99. Our model-based fair value is €0.6800, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evrofarma SA right now?
The price sits above even our optimistic bull case (€1.70). The favourable scenario is already priced in. The model range is unusually wide (€0.5100 to €1.70). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Evrofarma SA
How large is the market capitalisation of Evrofarma SA (EVROF)?
The market capitalisation of Evrofarma SA is €54.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evrofarma SA (EVROF)?
The price-to-sales ratio of Evrofarma SA is 1.58 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evrofarma SA (EVROF)?
Earnings per share at Evrofarma SA are €0.0790 (price ÷ EPS = P/E 50.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evrofarma SA (EVROF)?
The net margin of Evrofarma SA is 3.1% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evrofarma SA (EVROF)?
The return on equity (ROE) of Evrofarma SA is 18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evrofarma SA (EVROF)?
On an EBIT basis the return on assets of Evrofarma SA is 3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evrofarma SA (EVROF)?
The operating margin of Evrofarma SA is 8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evrofarma SA (EVROF)?
Revenue at Evrofarma SA is growing +4.3% versus a year earlier (3y avg +10.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Evrofarma SA (EVROF)?
Earnings per share at Evrofarma SA are growing +95.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Evrofarma SA in the live analysis
One click puts Evrofarma SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
